|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 104.80 EUR | +0.58% |
|
-2.87% | +1.26% |
| 12-04 | BioMérieux Launches Two Dedicated Equine Tests |  |
| 11-10 | UBS Maintains Buy Rating on BioMérieux, Confirms Price Target | |
Main competitors
| 1m. Revenue rev. | 4m. EPS revision | 4m. Revenue rev. | 1y. EPS revision | 1y. Revenue rev. | Visibility | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|
 | 14 | |||||||
| 22 | |||||||
| - | - | - | 9 | ||||
| 11 | |||||||
| 14 | |||||||
| 12 | |||||||
| 4 | |||||||
| - | - | - | - | ||||
| 14 | |||||||
| - | - | ||||||
| 4 | |||||||
| - | - | ||||||
| 2 | |||||||
| 3 | |||||||
| - | 1 | ||||||
| 4 | |||||||
| - | - | ||||||
| 8 | |||||||
| 1 | |||||||
| Average | 8 | |||||||
| Weighted average by Cap. | 13 |
- Stock Market
- Equities
- BIM Stock
- Sector bioMérieux
- Sector revisions
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition